Grail Stock Drops After Major Trial Fails
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: NASDAQ.COM
- Trial Setback: Grail's Galleri blood test failed to meet its primary endpoint in a major NHS England trial, leading to a significant stock drop in February, highlighting the gap between high market expectations and the current reality regarding FDA approval.
- Sales Growth Continues: Despite lacking FDA approval, Grail sells Galleri tests priced between $749 and $949 to affluent customers and hospitals, with over 56,000 tests sold in Q1, and projected revenue growth from $93 million in 2023 to $147 million in 2025, indicating strong market demand.
- Net Loss Reduction: Grail's net loss decreased significantly from $1.47 billion to $408 million between 2023 and 2025, demonstrating effective cost control alongside revenue growth, which enhances the company's financial health.
- Optimistic Future Outlook: Despite the trial setback, Grail expects revenue growth of 22%-32% in 2024, with analysts forecasting a 22% increase in 2026, reflecting confidence in the company's long-term potential, especially with potential insurance coverage following FDA approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 159.090
Low
40.50
Averages
133.54
High
170.00
Current: 159.090
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Executive Appointments: IQM Quantum Computers has appointed Craig Ciesla as Chief Technology Officer and Inés de Vega as Chief Scientist, aiming to strengthen the company's technological leadership in preparation for its upcoming Nasdaq listing.
- Technology Strategy Advancement: With over 25 years of experience in deep tech, Ciesla will be responsible for driving the implementation of IQM's technology strategy, playing a crucial role in accelerating the development of fault-tolerant quantum computing.
- Market Leadership: Having sold 23 quantum computers, IQM has established itself as a leader in superconducting quantum computing, and Ciesla's addition is expected to further solidify its market position in high-performance computing.
- Funding Progress: As the merger with Real Asset Acquisition Corp. advances, IQM successfully completed a $146 million PIPE financing in June, reflecting strong market confidence in its future growth.
See More
- Market Decline: On Wednesday, the S&P 500 Index fell by 1.62%, the Dow Jones Industrial Average dropped by 1.87%, and the Nasdaq 100 Index decreased by 1.98%, indicating a significant market reaction to rising geopolitical tensions that undermined investor confidence.
- Oil Price Surge: Crude oil prices rose over 2% due to escalating tensions in the Middle East, which not only exacerbated losses in stocks and bonds but also pressured airline and trucking companies, highlighting the profound impact of energy price fluctuations on the overall market.
- Stable Inflation Data: The US May Consumer Price Index rose 4.2% year-over-year, in line with expectations, while core CPI increased by 2.9%, alleviating some inflation concerns, although rising oil prices may reignite scrutiny over inflationary pressures.
- Tech Stock Retreat: Chipmakers and AI infrastructure stocks experienced significant declines, with Nvidia and Tesla both dropping over 3%, reflecting a waning confidence in tech stocks that could influence future investment strategies.
See More
- Market Decline: The S&P 500 Index fell by 0.61%, the Dow Jones Industrial Average dropped by 0.88%, and the Nasdaq 100 Index decreased by 0.80%, indicating investor concerns over chipmakers and AI infrastructure stocks, which reflects a weakening confidence in technology stocks.
- Inflation Data Impact: The US May Consumer Price Index rose by 4.2% year-on-year, meeting expectations and marking the fastest increase in three years, which, while easing inflation concerns, still affects market sentiment and leads to more cautious expectations regarding future interest rate policies.
- Pressure on Airlines and Transport: Trucking companies are under pressure as Amazon expanded its LTL freight service, with Old Dominion Freight Line and FedEx Freight down over 4% and 3% respectively, indicating growing concerns about increased competition in the transportation sector.
- Energy Stocks Rise: WTI crude oil prices increased by over 1%, boosting energy producers like Devon Energy by more than 5%, suggesting that despite overall market weakness, the energy sector's profit outlook remains optimistic amid geopolitical tensions.
See More
- Market Decline: The S&P 500 index fell by 0.28%, the Dow Jones Industrial Average dropped by 0.38%, and the Nasdaq 100 index decreased by 0.28%, indicating that weakness in technology stocks is dragging down the broader market as investors rotate out of the sector.
- Inflation Data Impact: The US May Consumer Price Index rose by 4.2% year-over-year, matching expectations and marking the fastest increase in three years, while the core CPI rose by 2.9%, also in line with forecasts, easing inflation concerns and limiting downside pressure on Treasury yields.
- Pressure on Trucking Sector: Amazon's expansion of its LTL freight service to all US destinations has led to significant declines in trucking companies, with ArcBest and Old Dominion Freight Line down over 7% and 6% respectively, reflecting market worries about the trucking industry's outlook.
- Energy Stocks Strength: WTI crude oil prices increased by more than 1%, boosting energy producers like Devon Energy, which rose over 4%, indicating that the energy sector retains resilience amid geopolitical tensions.
See More
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
- Upsized Funding Round: Element Biosciences successfully raised $175 million in its Series E funding round, primarily from long-time investor Samsung Electronics, aimed at advancing the commercialization of its genetic testing and research products.
- Product Line Expansion: The financing will support the commercialization of sequencing products like AVITI and VITARI, while also funding the upcoming launches of AVITI Dx and AVITI24, thereby enhancing the company's competitive edge in the gene sequencing market.
- Market Competition Landscape: In the gene sequencing market, Illumina remains the dominant player, while Roche is expanding its footprint through partnerships and investments in next-generation sequencing and molecular diagnostics, and Element's funding will help it increase market share in this competitive environment.
- International Strategy: Element stated that the funding will aid in expanding its international presence and support the development of future products for research, drug development, and diagnostics, further strengthening its global business footprint.
See More










